Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Region: Trend Outlook and Growth Opportunity
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Region: Trend Outlook and Growth Opportunity
Amyotrophic Lateral Sclerosis (ALS) Treatment Market by End User (Office Building Construction, Retail Construction, Hospitality Construction, Institutional Construction, Other End Users), by North America (United States, Canada, Mexico), by South America (Brazil, Argentina, Rest of South America), by Europe (United Kingdom, Germany, France, Italy, Spain, Russia, Benelux, Nordics, Rest of Europe), by Middle East & Africa (Turkey, Israel, GCC, North Africa, South Africa, Rest of Middle East & Africa), by Asia Pacific (China, India, Japan, South Korea, ASEAN, Oceania, Rest of Asia Pacific) Forecast - is a comprehensive report that provides insights into the market dynamics, including the key drivers, challenges, and opportunities shaping the industry landscape. It also delves into the competitive landscape, highlighting the major players and their strategies.
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
Global amyotrophic lateral sclerosis treatment market will reach $762.3 million by 2027, growing by 5.8% annually over 2020-2027 owing to the increasing geriatric population worldwide coupled with growing prevalence rate of ALS, and the increase in R&D for new amyotrophic lateral sclerosis therapies.
Highlighted with 80 tables and 67 figures, this 139-page report “Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Region: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire global amyotrophic lateral sclerosis treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global amyotrophic lateral sclerosis treatment market in every aspect of the classification from perspectives of Treatment Type, ALS Type, Distribution Channel, and Region.
Based on Treatment Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Medication
o Riluzole (Rilutek)
o Radicava (Edaravone)
o Tiglutik (Thickened Riluzole)
o Nuedexta
• Stem Cell Therapy
• Other Treatments
Based on ALS Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Sporadic ALS
• Familial ALS
Based on Distribution Channel, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
Geographically, the following regions together with the listed national/local markets are fully investigated:
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• North America (U.S., Canada, and Mexico)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (UAE, Saudi Arabia, South Africa)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of all regional markets by country and split of key national markets by Treatment Type, ALS Type, and Distribution Channel over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
AB Science SA
Amylyx Pharmaceuticals Inc.
Biogen Inc.
Biohaven Pharmaceutical Holding Co., Ltd.
BrainStorm Cell Limited
Corestem, Inc.
F.Hoffmann-La Roche AG
Ionis Pharmaceuticals, Inc.
Mitsubishi Tanabe Pharma Corporation
Otsuka Pharmaceutical Co., Ltd.
Sun Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of Market Research Methodology 13
1.2.2 Market Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 15
1.2.6 Market Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the Market 23
2.2 Major Growth Drivers 25
2.3 Market Restraints and Challenges 29
2.4 Emerging Opportunities and Market Trends 32
2.5 Porter’s Fiver Forces Analysis 36
3 Segmentation of Global Market by Treatment Type 40
3.1 Market Overview by Treatment Type 40
3.2 Medication 42
3.3 Stem Cell Therapy 44
3.4 Other Treatments 45
4 Segmentation of Global Market by ALS Type 46
4.1 Market Overview by ALS Type 46
4.2 Sporadic ALS 48
4.3 Familial ALS 49
5 Segmentation of Global Market by Distribution Channel 50
5.1 Market Overview by Distribution Channel 50
5.2 Hospital Pharmacies 52
5.3 Retail Pharmacies 53
5.4 Online Pharmacies 54
5.5 Other Distribution Channels 55
6 Segmentation of Global Market by Region 56
6.1 Geographic Market Overview 2020-2027 56
6.2 North America Market 2020-2027 by Country 60
6.2.1 Overview of North America Market 60
6.2.2 U.S. 63
6.2.3 Canada 66
6.2.4 Mexico 68
6.3 European Market 2020-2027 by Country 70
6.3.1 Overview of European Market 70
6.3.2 UK 73
6.3.3 France 75
6.3.4 Germany 77
6.3.5 Spain 79
6.3.6 Italy 81
6.3.7 Russia 83
6.3.8 Rest of European Market 85
6.4 Asia-Pacific Market 2020-2027 by Country 87
6.4.1 Overview of Asia-Pacific Market 87
6.4.2 China 90
6.4.3 Japan 92
6.4.4 India 95
6.4.5 Australia 97
6.4.6 South Korea 99
6.4.7 Rest of APAC Region 101
6.5 South America Market 2020-2027 by Country 103
6.5.1 Argentina 106
6.5.2 Brazil 108
6.5.3 Chile 110
6.5.4 Rest of South America Market 112
6.6 MEA Market 2020-2027 by Country 113
6.6.1 UAE 116
6.6.2 Saudi Arabia 118
6.6.3 South Africa 120
6.6.4 Other National Markets 122
7 Competitive Landscape 123
7.1 Overview of Key Vendors 123
7.2 New Product Launch, Partnership, Investment, and M&A 126
7.3 Company Profiles 127
AB Science SA 127
Amylyx Pharmaceuticals Inc. 129
Biogen Inc. 130
Biohaven Pharmaceutical Holding Co., Ltd. 131
BrainStorm Cell Limited 132
Corestem, Inc. 133
F.Hoffmann-La Roche AG 134
Ionis Pharmaceuticals, Inc. 135
Mitsubishi Tanabe Pharma Corporation 136
Otsuka Pharmaceutical Co., Ltd. 137
Sun Pharmaceutical Industries Ltd. 138
RELATED REPORTS 139
Research Methodology:
Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|